Pelthos Therapeutics Inc. - 10-Q Filing

Pelthos Therapeutics reports Q3 2026 results featuring significant customer concentration and complex debt structures involving Series A/C preferred stock.

SEC EDGAR ·

Tickers: $PTHS

Read the full article at SEC EDGAR

More Regulatory news